OC
CADL icon

Oppenheimer & Co’s Candel Therapeutics CADL Stock Holding History

Oppenheimer & Co’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-37,915
Closed -$329K – 1584
2024
Q4 		$329K Buy
+37,915
New +$224K ﹤0.01% 1220

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Oppenheimer & Co's CADL Position: Q1 2025 in Review

Oppenheimer & Co sold out of Candel Therapeutics (CADL) in Q1 2025, closing a stake of 37,915 shares — an estimated $329K sold.

Oppenheimer & Co first reported a position in CADL in Q4 2024 and held it in 1 quarter. The position peaked at $329K in Q4 2024. 82 funds tracked by Wall St. Rank hold CADL as of Q1 2025.

  • Oppenheimer & Co reported no remaining Candel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 37,915 Candel Therapeutics shares in Q1 2025, an estimated $329K.
  • Oppenheimer & Co first reported a position in Candel Therapeutics in Q4 2024 and held it in 1 quarter.
  • Oppenheimer & Co's Candel Therapeutics position peaked at $329K in Q4 2024.
  • 82 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2025.

Based on Oppenheimer & Co's 13F filing for Q1 2025, filed 23 Apr 2025.